1. Home
  2. Directory
  3. NPI Profile
  4. Prescriptions 1104822949

DR. NILDA SANTIAGO GARCIA M.D.
Prescription History 1104822949
Specialist in Ponce, PR

NPI Status: Active since June 27, 2005

Contact Information

471 AVE. FERROCARRIL
SUITE #17
PONCE, PR
ZIP 00717
Phone: (787) 259-8212
Fax: (787) 848-7979

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. NILDA SANTIAGO GARCIA M.D., an active Specialist specialist practicing in Ponce, PR. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 23 documented patient claims. Among these therapy options, the most frequently utilized medication is Synthroid, which accounts for 12 claims alone.

Medication Index

S
V
No matching medications currently found on file.

Synthroid

Generic Formulation: Levothyroxine SodiumSpecialty: Specialist
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
PR State Average Benchmarks
Peer Average Claims214.0
Peer Average 30-Day Fills350.5
Peer Average Days Supply10,488
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 94.4% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $603.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$50.28

State Avg Cost Per Claim

$70.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Valsartan

Generic Formulation: ValsartanSpecialty: Specialist
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
PR State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills81.8
Peer Average Days Supply2,449
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.8% less volume than the regional standard for practitioners inside PR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $173.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.80

State Avg Cost Per Claim

$39.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.

Therapeutic Applications

Valsartan is used to treat high blood pressure and heart failure. It is also used to improve the chance of living longer after a heart attack. In people with heart failure, it may also lower the chance of having to go to the hospital for heart failure. Valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. NILDA SANTIAGO GARCIA M.D. provides transparency into local medical care patterns within Ponce, PR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.